In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)
Wegovy, Mounjaro, Zepbound) are mostly single-use and require multiple devices per month, while pen injectors (e.g., Ozempic) are multi-use, needing fewer devices overall
Schwab et al., 2014) Eradication is difficult for many of these pathogens due to the increased viscoelasticity of the mucus, antibiotic resistance of the bacteria, and antibiotic tolerance from biofilm formation of bacteria within the mucus (Singh et al., 2000
To realize their full therapeutic potential, future research must rigorously address several critical dimensions, which collectively form a roadmap for the field
A patch test before full application is recommended, and anyone with Wilson's disease or who is pregnant should consult a healthcare professional before use
632 Thus, further studies uncovering the tissue specific CD38 activities will facilitate the development of clinical application of CD38 inhibitors
